精神病性与情感障碍中紧张症复发的危险因素
该回顾性队列研究纳入印度三级神经精神中心303例紧张症患者,随访至78个月,发现48.8%患者复发,复发风险在指数发作后2年内最高。
要点
- 紧张症复发率高,近半数患者复发,风险集中在指数发作后2年内。
- 出院时使用抗精神病药与复发风险降低41.1%及更长复发时间相关。
- 精神病性与情感谱系障碍诊断与复发率或复发时间无关。
核心结论
- 紧张症是复发性疾病,近半数患者复发,尤其在前2年内。
- 抗精神病药治疗可能对预防复发起关键作用,强调关键期维持治疗的必要性。
- 潜在精神科诊断(精神病性 vs 情感谱系)与复发率或复发时间无关。
研究设计与样本
- 回顾性队列研究,在印度三级神经精神中心进行。
- 共分析303例紧张症患者。
主要发现
- 148例(48.8%)患者复发,155例(55.2%)未复发。
- 复发患者平均(SD)年龄30.09(9.54)岁,女性80例(60.7%),精神病性谱系障碍94例(63.5%)。
- 未复发患者平均(SD)年龄31.27(11.80)岁,女性93例(60.0%),精神病性谱系障碍97例(62.6%)。
- 中位(IQR)随访29.8(10.8-47.0)个月。
- 复发风险在指数发作后2年内最高。
关键数值与推荐
- 潜在精神科诊断(精神病性 vs 情感谱系障碍)与复发率或复发时间无关。
临床怎么用
- 对紧张症患者出院时应考虑抗精神病药维持治疗,尤其在指数发作后2年内的关键期。
- 长期管理策略需关注预防复发,并根据复发风险进行随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Catatonia is a recurrent syndrome, yet the risk factors associated with its long-term course and relapse remain poorly understood. This study yields insights into the time to relapse in catatonia. It also characterizes the demographic, clinical, and treatment-related factors associated with relapse across psychotic and affective spectrum disorders. OBJECTIVE: To examine the relapse rate of catatonia and identify factors associated with relapse, particularly in patients with psychotic and affective spectrum disorders, over an extended follow-up period. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted at a tertiary neuropsychiatric center in India. Patients who presented with catatonia to emergency psychiatry and acute care services between January 2014 and December 2017 were included. Follow-up was up to 78 months, with the final follow-up completed in December 2020. Data were analyzed in November 2024. EXPOSURES: Catatonia in psychotic or affective spectrum disorders. MAIN OUTCOMES AND MEASURES: The primary outcome was catatonia relapse defined as the recurrence of catatonic symptoms during follow-up. Survival analysis included Kaplan-Meier curves, log-rank tests, and Cox proportional hazards regression to assess time to relapse and identify factors associated with relapse risk. RESULTS: Of 303 patients with catatonia included in the analysis, relapse occurred in 148 (48.8%; mean [SD] age, 30.09 [9.54] years; 80 females [60.7%]; 94 [63.5%] with psychotic spectrum disorder) over a median (IQR) follow-up of 29.8 (10.8-47.0) months, while 155 patients (55.2%; mean [SD] age, 31.27 [11.80] years; 93 females [60.0%]; 97 [62.6%] with psychotic spectrum disorder) had no relapse. Relapse risk was highest within 2 years of an index episode. Antipsychotic prescriptions at discharge were associated with longer times to relapse and a relapse risk reduction of 41.1% (hazard ratio, 0.59; 95% CI, 0.38-0.92; P = .02). The underlying psychiatric diagnosis (psychotic vs affective spectrum disorder) was not associated with relapse rates or time to relapse. CONCLUSIONS AND RELEVANCE: Catatonia is a recurrent condition, with nearly half of patients experiencing relapses, particularly within the first 2 years. Antipsychotic treatment may play a crucial role in relapse prevention, emphasizing the need for maintenance therapy during this critical period. While preliminary, these findings highlight the importance of evolving long-term management strategies to prevent catatonia relapse and call for further research into the pathophysiological mechanisms underlying catatonia.
引用
- Pathak H, Susan Varghese S, Suhas S, et al. Risk Factors for Catatonia Relapse in Psychotic and Affective Disorders. JAMA Psychiatry. 2025. PMID: 40737013. doi:10.1001/jamapsychiatry.2025.1818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。